the sell off, page-6

We've seen a couple of sell-offs like this last year when one of the funds decided to offload a big chunk of stock for reasons still unknown. The recent market action wreaks of someone offloading a large number of shares but whether this constitutes a forewarning of bad news or simply portfolio rebalancing only time will tell.

I remind myself during these sell-offs that the market that TIS is pursuing is now around the $6 billion mark and could well double over the next ten years given the baby boomers aging phenomenon and the diabetes and obesity pandemics that continue to cut a swath across the globe.

With a market cap of around $85m, TIS needs only a 1% share and a half decent profit margin/royalty rate of this $6 billion and growing market to be considered to be quite cheap. Hopefully the potential shown in previous clinical trials continues with this current trial and when Vitrogro is released on to the market the 1% market penetration figure proves quite conservative. Let's hope.

Good luck to all.